Skip to main content
    P

    Pmv Pharmaceuticals Inc (PMVP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.29
    +0.05 (+4.03%)

    Market Cap: $93.64M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(15/24)
    Avg Surprise
    +6.51%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.34
    Range$-0.41 - $-0.25
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.35+3.8%
    60d ago$-0.35+3.8%
    30d ago$-0.35+3.8%
    7d ago$-0.39+11.7%
    Current$-0.34
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.29 - $0.10
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.16---
    Sep 26EST
    		-$-0.34---
    Jun 26
    Reported Aug 13
    		$-0.34$-0.38+10.53%Beat+17.1%
    Mar 26
    Reported May 12
    		$-0.34$-0.38+10.53%Beat+0.0%
    Dec 25
    Reported Mar 6
    		$-0.34$-0.41+18.07%Beat+24.4%
    Sep 25
    Reported Nov 12
    		$-0.40$-0.40+0.00%Beat-8.1%
    Jun 25
    Reported Aug 7
    		$-0.41$-0.39-5.13%Miss-1950.0%
    Mar 25
    Reported May 9
    		$-0.34$-0.38+10.53%Beat-13.3%
    Dec 24
    Reported Mar 3
    		$-0.45$-0.38-18.42%Miss-45.2%
    Sep 24
    Reported Nov 7
    		$-0.37$-0.36-2.78%Miss-8.8%
    Jun 24
    Reported Aug 8
    		$-0.02N/A+94.44%Beat+94.7%
    Mar 24
    Reported May 9
    		$-0.30$-0.37+18.92%Beat+28.6%
    Dec 23
    Reported Feb 29
    		$-0.31$-0.39+20.51%Beat+27.9%
    Sep 23
    Reported Nov 9
    		$-0.34$-0.45+24.44%Beat+15.0%
    Jun 23
    Reported Aug 9
    		$-0.38$-0.47+19.15%Beat+0.0%
    Mar 23
    Reported May 10
    		$-0.42$-0.46+8.70%Beat-2.4%
    Dec 22
    Reported Mar 1
    		$-0.43$-0.44+2.27%Beat-7.5%
    Sep 22
    Reported Nov 8
    		$-0.40$-0.41+2.44%Beat-21.2%
    Jun 22
    Reported Aug 9
    		$-0.38$-0.41+7.32%Beat-31.0%
    Mar 22
    Reported May 10
    		$-0.41$-0.39-5.13%Miss-57.7%
    Dec 21
    Reported Mar 1
    		$-0.40$-0.35-14.29%Miss+36.5%
    Sep 21
    Reported Nov 12
    		$-0.33$-0.30-10.00%Miss+49.2%
    Jun 21
    Reported Aug 13
    		$-0.29$-0.28-3.57%Miss+39.6%
    Mar 21
    Reported May 14
    		$-0.26$-0.24-8.33%Miss-
    Dec 20
    Reported Mar 3
    		$-0.63$-0.67+5.97%Beat-
    Sep 20
    Reported Nov 13
    		$-0.65$-0.50-30.00%Miss-
    Jun 20
    Reported Sep 25
    		$-0.48$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.91EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-70.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage17.78x
    Current Ratio7.70xQuick Ratio7.70x
    Trading Statistics
    Beta1.35Avg Volume891.96K
    52-Week High$1.9152-Week Low$1.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.50
    SMA 20$1.49
    SMA 50$1.37
    SMA 200$1.30
    EMA 10$1.42
    EMA 20$1.45
    EMA 50$1.40
    EMA 200$1.31

    MACD

    Line: -0.01Signal: 0.04Hist: -0.04

    ADX

    ADX: 18.7+DI: 20.0-DI: 25.9

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down96.0
    PSAR$1.84

    Bollinger Bands

    Upper Band$1.81
    Lower Band$1.16
    %B Position4381%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    41.4

    Momentum Oscillators

    Stoch %K7.1
    Stoch %D13.8
    Williams %R-91.2
    ROC (10d)-26.3%
    Momentum-0.46
    CCI (20d)-113.3
    MFI (14d)72.4

    Volatility Measures

    ATR (14d)$0.13(9.9%)
    StdDev (20d)0.16
    Hist Vol99.2%(High)

    Volume Flow

    VWAP$1.29
    OBV-2.3M
    AD Line-27.2M
    CMF (20d)0.035

    Volume Metrics

    Avg Vol (20d)908.5K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.60

    Pivot Points

    R3$1.47
    R2$1.42
    R1$1.33
    Pivot Point$1.28
    S1$1.19
    S2$1.14
    S3$1.05

    Advanced Oscillators

    TSI-0.72
    Ultimate Osc30.7
    KST114.22

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$1.62M$0
    Cost of Revenue$0$0$33,000$0$0$0N/A$0$0$0$359,000$0
    Gross Profit$0$0$-33,000$0$0$0N/A$0$0$0$-359,000$0
    Operating Expenses$18.88M$19.02M$19.24M$22.52M$22.88M$21.56M$25.17M$21.89M$20.17M$18.22M$18.90M$19.63M
    R&D$14.68M$15.33M$15.83M$18.21M$18.40M$17.44M$13.77M$16.95M$14.63M$13.19M$13.38M$13.59M
    SG&A$4.21M$3.69M$3.42M$4.31M$4.48M$4.12M$11.40M$4.94M$5.54M$5.04M$5.52M$6.04M
    Operating Income$-18,881,000$-19,019,000$-19,241,000$-22,522,000$-22,879,000$-21,564,000$-25,169,000$-21,888,000$-20,170,000$-18,221,000$-18,902,000$-19,628,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-788,000$-980,000$-1,232,000$-1,480,000$-1,690,000$-1,935,000$-2,287,000$-2,615,000$-2,801,000$-2,952,000$-3,166,000$-2,984,000
    Income Before Tax$-18,083,000$-18,038,000$-18,011,000$-21,065,000$-21,205,000$-19,633,000$-23,001,000$-19,152,000$-17,386,000$-15,270,000$-15,758,000$-16,640,000
    Income Tax Expense$3,000$0$26,000$-6,000$5,000$-2,197,000$-1,000$74,000$-16,173,000$0$-2,000$0
    Net Income$-18,086,000$-18,038,000$-18,037,000$-21,059,000$-21,210,000$-17,436,000$-23,000,000$-19,226,000$-1,213,000$-15,270,000$-15,756,000$-16,640,000
    EBITDA$-19,229,000$-19,370,000$-19,721,000$-23,208,000$-23,587,000$-22,367,000$-26,262,000$-22,631,000$-21,191,000$-19,488,000$-20,418,000$-21,108,000
    EBIT$-18,871,000$-19,019,000$-19,241,000$-22,545,000$-22,895,000$-21,564,000$-25,169,000$-21,767,000$-20,187,000$-18,222,000$-18,902,000$-19,624,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PMVP

    News

    PMV appoints Matt Eckler: what the 2027 filing means for PMV Pharmaceuticals stock

    PMV Pharmaceuticals has appointed Matt Eckler to its board and plans a New Drug Application filing for rezatapopt in the first quarter of 2027. This follows positive clinical data from the PYNNACLE trial...

    ad-hoc-news.de•10/16/26•Somewhat-Bullish

    PMV Pharmaceuticals adds Matt Eckler and PMV Pharmaceuticals stock posts 21.60 percent YTD

    PMV Pharmaceuticals (PMVP) has gained 21.60% year-to-date by October 12, 2026, while adding Matt Eckler to its board on October 5, 2026. The company is preparing for a first-quarter 2027 regulatory filing for rezatapopt...

    ad-hoc-news.de•10/13/26•Bullish

    PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

    PMV Pharmaceuticals (PMVP) has seen its stock rise by 19% in the last three months, driven by positive clinical data for its lead drug candidate, rezatapopt...

    TradingView•10/12/26•Bullish

    PMV Pharmaceuticals stock adds Matt Eckler to its board opening the next clinical chapter

    PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its board of directors, coinciding with the completion of enrollment for the monotherapy portion of its Phase 2 PYNNACLE trial. This strategic move strengthens...

    AD HOC NEWS•10/7/26•Bullish

    PMV PHARMACEUTICALS APPOINTS MATT ECKLER, PH.D., TO BOARD OF DIRECTORS

    PMV Pharmaceuticals has announced the appointment of Matt Eckler, Ph.D., to its Board of Directors. Dr. Eckler brings significant experience in the pharmaceutical and biotechnology sectors...

    Moomoo•10/6/26•Somewhat-Bullish

    PMVP Valuation and Fair Value

    P/E
    -0.9x
    P/B
    1.0x
    See GNG's fair value

    PMVP Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -70.9%

    PMVP Competitors

    CompanyTicker
    Rani Therapeutics Holdings IncRANI
    Anixa Biosciences IncANIX
    Milestone Pharmaceuticals IncMIST
    Insight Molecular Diagnostics Inc.IMDX
    ImmuCell CorporationICCC
    OnKure Therapeutics, Inc.OKUR
    Coya Therapeutics, Inc. Common StockCOYA
    Biomea Fusion IncBMEA

    Sector: Healthcare

    PMVP Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PMVP Bull Case vs Bear Case

    Bull case

    • 100.0% of PMVP's analyst ratings are Buy or Strong Buy.

    PMVP Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    2.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.34
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About PMVP

    Does PMVP pay dividends?

    Pmv Pharmaceuticals Inc (PMVP) does not currently pay a regular dividend.

    What is PMVP's market cap?

    Pmv Pharmaceuticals Inc (PMVP) has a market capitalization of $93.64M with a current stock price of $1.29.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In